Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9919058 | 0.86 | L3MBTL1 (0.59) | F2RL3L3MBTL1ALDH1A1IP6K1KMT2A | |
| SCHEMBL7600928 | 0.81 | L3MBTL1 (0.49) | F2RL3L3MBTL1ALDH1A1IP6K1KMT2A | |
| SCHEMBL12177224 | 0.79 | L3MBTL1 (0.48) | F2RL3L3MBTL1ALDH1A1IP6K1KDM4E | |
| SCHEMBL1500289 | 0.79 | L3MBTL1 (0.48) | L3MBTL1ALDH1A1IP6K1KMT2AKDM4E | |
| SCHEMBL5312155 | 0.79 | L3MBTL1 (0.48) | L3MBTL1ALDH1A1IP6K1KDM4EACVR1 | |
| SCHEMBL30186355 | 0.79 | ESR1 (0.62) | L3MBTL1ALDH1A1IP6K1KDM4EACVR1 | |
| SCHEMBL12825983 | 0.79 | CYP1A2 (0.47) | ALDH1A1PDE5AKMT2ARAB9ANR4A2 | |
| SCHEMBL2040470 | 0.78 | KDM4E (0.46) | L3MBTL1ALDH1A1IP6K1KMT2AKDM4E | |
| SCHEMBL9217204 | 0.77 | DPP4 (0.44) | ALDH1A1NR4A2SOS2CYP1A2 | |
| SCHEMBL25111597 | 0.77 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1IP6K1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12496297-B1 | Compositions of autophagy modulating agents and uses thereof | WASHINGTON UNIVERSITY (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4337662-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | Bridge Medicines (US) | 2024-03-20 | — | — | EP | disclosed |
| WO-2022240830-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | BRIDGE MEDICINES (US) | 2022-11-17 | — | — | WO | disclosed |
| US-9655363-B2 | Microbiocides | SYNGENTA PARTICIPATIONS AG (CH) | 2017-05-23 | — | — | US | disclosed |
| US-9655363-B2 | Microbiocides | SYNGENTA PARTICIPATIONS AG (CH) | 2017-05-23 | — | — | US | disclosed |
| EP-2951167-B1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-01-25 | — | — | EP | disclosed |
| US-20150351402-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2015-12-10 | — | — | US | disclosed |
| US-20150351402-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2015-12-10 | — | — | US | disclosed |
| US-20140221405-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8524721-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| WO-2011032159-A1 | METHODS TO PREVENT A HAIR-RELATED SIDE EFFECT OF TREATMENT WITH A CHEMOTHERAPEUTIC AGENT | META COMESTICS, LLC (US) | 2011-03-17 | — | — | WO | disclosed |
| US-20110002866-A1 | METHODS TO PREVENT A HAIR-RELATED SIDE EFFECT OF TREATMENT WITH A CHEMOTHERAPEUTIC AGENT | LUBIT BEVERLY W | 2011-01-06 | — | — | US | disclosed |
| US-20100234350-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| WO-2010039535-A1 | COMPOSITIONS AND METHODS TO TREAT EPITHELIAL-RELATED CONDITIONS | META COSMETICS, LLC (US) | 2010-04-08 | — | — | WO | disclosed |
| US-7622474-B2 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622474-B2 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110002866-A1 | METHODS TO PREVENT A HAIR-RELATED SIDE EFFECT OF TREATMENT WITH A CHEMOTHERAPEUTIC AGENT | PGF, PTGS1, PTGS2 | F2RL3 4779/4885L3MBTL1 2318/4885ALDH1A1 498/4885 |
| US-20100234350-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | F2RL3 118/4885L3MBTL1 4542/4885ALDH1A1 1369/4885 |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PIGS, GP6, ASGR1 | F2RL3 1647/4885L3MBTL1 3635/4885ALDH1A1 1520/4885 |
| US-20140221405-A1 | PLATELET ADP RECEPTOR INHIBITORS | PTAFR, ADGRF1, P2RY6 | F2RL3 113/4885L3MBTL1 4704/4885ALDH1A1 760/4885 |
| US-20150351402-A1 | NOVEL MICROBIOCIDES | MSR1, C1R, CD14 | F2RL3 64/4885L3MBTL1 644/4885ALDH1A1 2776/4885 |
| US-12496297-B1 | Compositions of autophagy modulating agents and uses thereof | BECN1, TFEB, ATG7 | F2RL3 4387/4885L3MBTL1 2665/4885ALDH1A1 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.